Non-muscle invasive bladder cancer

• Dose expansion, safety and efficacy study of intravesical instillation of TARA-002 in adults with high-grade non-muscle invasive bladder can … Not authorised
  2023-505062-28-00 9
• PROSPECTIVE RANDOMISED CLINICAL TRIAL TO EVALUATE THE EARLY RECURRENCE RATE IN NON-MUSCLE INVASIVE BLADDER CANCER BETWEEN THE USE OF CHEMOHY … Pending
  2024-519890-21-00 11
• Study to evaluate the efficacy and safety of supportive mitomycin C administered via electric current in the treatment of non-muscle invasiv … Recruiting
  2024-520006-19-00 6 2021-12-15
• CLINICAL TRIAL TO EVALUATE BLADDER INSTILLATION OF NEOADJUVANT CHEMOTHERAPY TO TRANSURETHRAL RESECTION OF THE BLADDER FOR THE PREVENTION OF … Recruiting
  2024-512683-53-00 6 2018-05-18
• A phase II prospective, open-label, multi-centre, single arm study of sasanlimab plus sacituzumab govitecan in BCG (Bacillus Calmette-Guérin … Recruitment ended
  2024-518486-10-00 4 2023-02-23
• A Phase 3 Single-Arm Study of UGN-102 for Treatment of LG IR NMIBC Recruitment ended
  2023-506680-34-00 5 2022-03-24
• CREST - Phase 3 Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) or as a Single Agent in Participants Wi … Recruitment ended
  2023-509089-39-00 5 2020-07-01
• Study to evaluate the efficacy and safety of Durvalumab(MEDI4736) in combination with intravesical BCG for the treatment of patients diagnos … Recruitment ended
  2023-505341-23-00 5 2018-07-27
• A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) Ended
  2023-508404-37-00 3 2022-10-26
• A study of enfortumab vedotin given in the bladder for treatment of patients with non-muscle invasive bladder cancer (NMIBC). Ended
  2023-503388-40-00 3 2021-08-24
• A Study Testing a New Drug (ALT-803) With BCG to Treat Early-Stage Bladder Cancer Ended
  2025-521223-78-00 4

Showing 1–11 of 11 trials